Stroke; a journal of cerebral circulation
-
Randomized Controlled Trial Multicenter Study
Significance of intraventricular hemorrhage in acute intracerebral hemorrhage: intensive blood pressure reduction in acute cerebral hemorrhage trial results.
Intraventricular hemorrhage (IVH) with spontaneous intracerebral hemorrhage indicates a poor prognosis but uncertainty exists over the pattern of association. We aimed to elucidate risk associations of IVH and outcome in the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) data set. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00716079.
-
Randomized Controlled Trial Multicenter Study
Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.
Our aim was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic intracranial hemorrhage or low chance of benefit when treated with alteplase (recombinant tissue-type plasminogen activator). ⋯ http://www.controlled-trials.com. Unique identifier: ISRCTN25765518. http://www.controlled-trials.com/ISRCTN25765518.
-
Randomized Controlled Trial
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke. We have investigated whether the effect of treatment is different in different subtypes of ischemic stroke. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00120003.
-
Multicenter Study Clinical Trial
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01654445.